CATX

SEC source: 0002064832-26-000318 · form4.xml · nonDerivative · entry 2

Lantheus Alpha Therapy, LLC · CIK 0002010224 · 10% owner

Lantheus Holdings, Inc. · CIK 0001521036 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,273,364

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.0448 to $3.1775, inclusive. The reporting person undertakes to provide to CATX, any security holder of CATX or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.

F2 · ownership.direct: Represents securities directly held by Lantheus Alpha Therapy, LLC ("Lantheus"), a wholly owned indirect subsidiary of Lantheus Holdings, Inc. ("Lantheus Holdings"). Under SEC rules and regulations, Lantheus Holdings may be deemed to have indirect beneficial ownership of the shares held by Lantheus, which has direct beneficial ownership.

SEC source: 0002064832-26-000318 · form4.xml · nonDerivative · entry 1

Lantheus Alpha Therapy, LLC · CIK 0002010224 · 10% owner

Lantheus Holdings, Inc. · CIK 0001521036 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,440,513

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.05 to $3.13, inclusive. The reporting person undertakes to provide to Perspective Therapeutics, Inc. ("CATX"), any security holder of CATX or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.

F2 · ownership.direct: Represents securities directly held by Lantheus Alpha Therapy, LLC ("Lantheus"), a wholly owned indirect subsidiary of Lantheus Holdings, Inc. ("Lantheus Holdings"). Under SEC rules and regulations, Lantheus Holdings may be deemed to have indirect beneficial ownership of the shares held by Lantheus, which has direct beneficial ownership.

SEC source: 0002064832-26-000316 · form4.xml · nonDerivative · entry 1

Lantheus Alpha Therapy, LLC · CIK 0002010224 · 10% owner

Lantheus Holdings, Inc. · CIK 0001521036 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,521,296

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.025 to $3.235, inclusive. The reporting person undertakes to provide to Perspective Therapeutics, Inc. ("CATX"), any security holder of CATX or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.

F2 · ownership.direct: Represents securities directly held by Lantheus Alpha Therapy, LLC ("Lantheus"), a wholly owned indirect subsidiary of Lantheus Holdings, Inc. ("Lantheus Holdings"). Under SEC rules and regulations, Lantheus Holdings may be deemed to have indirect beneficial ownership of the shares held by Lantheus, which has direct beneficial ownership.

SEC source: 0002064832-26-000314 · form4.xml · nonDerivative · entry 2

Lantheus Alpha Therapy, LLC · CIK 0002010224 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,563,425

F1 · shares: Effective June 14, 2024, Perspective Therapeutics, Inc. ("CATX") effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split.

F2 · shares: These sales were previously reported in Form 4s filed by Lantheus Holdings, Inc. on September 2, 2026 and September 3, 2026.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.08 to $3.165, inclusive. The reporting person undertakes to provide to CATX, any security holder of CATX or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.

F1 · balance_after: Effective June 14, 2024, Perspective Therapeutics, Inc. ("CATX") effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split.

F2 · balance_after: These sales were previously reported in Form 4s filed by Lantheus Holdings, Inc. on September 2, 2026 and September 3, 2026.

F5 · ownership.direct: Represents securities directly held by Lantheus Alpha Therapy, LLC ("Lantheus"), a wholly owned indirect subsidiary of Lantheus Holdings, Inc. ("Lantheus Holdings"). Under SEC rules and regulations, Lantheus Holdings may be deemed to have indirect beneficial ownership of the shares held by Lantheus, which has direct beneficial ownership.

SEC source: 0002064832-26-000310 · form4.xml · nonDerivative · entry 1

Lantheus Holdings, Inc. · CIK 0001521036 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,563,425

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.08 to $3.165, inclusive. The reporting person undertakes to provide to Perspective Therapeutics, Inc. ("CATX"), any security holder of CATX or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.

F2 · ownership.direct: Represents securities directly held by Lantheus Alpha Therapy, LLC ("Lantheus"), a wholly owned indirect subsidiary of Lantheus Holdings, Inc. ("Lantheus Holdings"). Under SEC rules and regulations, Lantheus Holdings may be deemed to have indirect beneficial ownership of the shares held by Lantheus, which has direct beneficial ownership.

SEC source: 0002064832-26-000314 · form4.xml · nonDerivative · entry 1

Lantheus Alpha Therapy, LLC · CIK 0002010224 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,599,194

F1 · shares: Effective June 14, 2024, Perspective Therapeutics, Inc. ("CATX") effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split.

F2 · shares: These sales were previously reported in Form 4s filed by Lantheus Holdings, Inc. on September 2, 2026 and September 3, 2026.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.095 to $3.165, inclusive. The reporting person undertakes to provide to CATX, any security holder of CATX or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

F1 · balance_after: Effective June 14, 2024, Perspective Therapeutics, Inc. ("CATX") effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split.

F2 · balance_after: These sales were previously reported in Form 4s filed by Lantheus Holdings, Inc. on September 2, 2026 and September 3, 2026.

F5 · ownership.direct: Represents securities directly held by Lantheus Alpha Therapy, LLC ("Lantheus"), a wholly owned indirect subsidiary of Lantheus Holdings, Inc. ("Lantheus Holdings"). Under SEC rules and regulations, Lantheus Holdings may be deemed to have indirect beneficial ownership of the shares held by Lantheus, which has direct beneficial ownership.

SEC source: 0002064832-26-000308 · form4.xml · nonDerivative · entry 1

Lantheus Holdings, Inc. · CIK 0001521036 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,599,194

F1 · shares: Effective June 14, 2024, Perspective Therapeutics, Inc. ("CATX") effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.095 to $3.165, inclusive. The reporting person undertakes to provide to CATX, any security holder of CATX or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

F1 · balance_after: Effective June 14, 2024, Perspective Therapeutics, Inc. ("CATX") effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split.

F3 · ownership.direct: Represents securities directly held by Lantheus Alpha Therapy, LLC ("Lantheus"), a wholly owned direct subsidiary of Lantheus Holdings, Inc. ("Lantheus Holdings"). Under SEC rules and regulations, Lantheus Holdings may be deemed to have indirect beneficial ownership of the shares held by Lantheus, which has direct beneficial ownership.

SEC source: 0001761768-26-000003 · ownership.xml · derivative · entry 1

Martinez Maria E · CIK 0001761768 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2036-03-02

F1 · date: The option grant was approved by the Issuer's Board of Directors on January 26, 2026, with a grant date of March 2, 2026, and represents the Reporting Person's annual equity award for 2026.

F2 · derivative.exercise_date: Option vests in full on March 2, 2027, subject to the Reporting Person's continued service on the vesting date.

SEC source: 0001748615-26-000002 · ownership.xml · derivative · entry 1

Morich Frank · CIK 0001748615 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2036-03-02

F1 · date: The option grant was approved by the Issuer's Board of Directors on January 26, 2026, with a grant date of March 2, 2026, and represents the Reporting Person's annual equity award for 2026.

F2 · derivative.exercise_date: Option vests in full on March 2, 2027, subject to the Reporting Person's continued service on the vesting date.

SEC source: 0001397331-26-000002 · ownership.xml · derivative · entry 1

Williamson Robert F III · CIK 0001397331 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2036-03-02

F1 · date: The option grant was approved by the Issuer's Board of Directors on January 26, 2026, with a grant date of March 2, 2026, and represents the Reporting Person's annual equity award for 2026.

F2 · derivative.exercise_date: Option vests in full on March 2, 2027, subject to the Reporting Person's continued service on the vesting date.

SEC source: 0001283301-26-000008 · ownership.xml · derivative · entry 1

HENSON HEIDI · CIK 0001283301 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2036-03-02

F1 · date: The option grant was approved by the Issuer's Board of Directors on January 26, 2026, with a grant date of March 2, 2026, and represents the Reporting Person's annual equity award for 2026.

F2 · derivative.exercise_date: Option vests in full on March 2, 2027, subject to the Reporting Person's continued service on the vesting date.

SEC source: 0001393007-26-000002 · ownership.xml · derivative · entry 1

Woods Lori A · CIK 0001393007 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2036-03-02

F1 · date: The option grant was approved by the Issuer's Board of Directors on January 26, 2026, with a grant date of March 2, 2026, and represents the Reporting Person's annual equity award for 2026.

F2 · derivative.exercise_date: Option vests in full on March 2, 2027, subject to the Reporting Person's continued service on the vesting date.

SEC source: 0001535289-26-000003 · ownership.xml · derivative · entry 1

Spoor Johan M. · CIK 0001535289 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 735,000

Underlying: Common Stock · 735,000 shares

Expires 2036-03-02

F1 · date: The option grant was approved by the Issuer's Board of Directors on January 26, 2026, with a grant date of March 2, 2026 (the "Grant Date"), and represents the Reporting Person's annual equity award for 2026.

F2 · derivative.exercise_date: Option vests and becomes exercisable over four years in 48 substantially equal monthly installments beginning on the date that is one month after the Grant Date, subject to the Reporting Person's continued service on each vesting date.

SEC source: 0001375410-26-000003 · ownership.xml · derivative · entry 1

Hunt Jonathan Robert · CIK 0001375410 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 90,000 shares

Expires 2036-03-02

F1 · date: The option grant was approved by the Compensation Committee of the Issuer's Board of Directors on February 4, 2026, with a grant date of March 2, 2026 (the "Grant Date"), and represents the Reporting Person's annual equity award for 2026.

F2 · derivative.exercise_date: Option vests and becomes exercisable over four years in 48 substantially equal monthly installments beginning on the date that is one month after the Grant Date, subject to the Reporting Person's continued service on each vesting date.

SEC source: 0001965071-26-000002 · ownership.xml · derivative · entry 1

Puhlmann Markus · CIK 0001965071 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2036-03-02

F1 · date: The option grant was approved by the Compensation Committee of the Issuer's Board of Directors on February 4, 2026, with a grant date of March 2, 2026 (the "Grant Date"), and represents the Reporting Person's annual equity award for 2026.

F2 · derivative.exercise_date: Option vests and becomes exercisable over four years in 48 substantially equal monthly installments beginning on the date that is one month after the Grant Date, subject to the Reporting Person's continued service on each vesting date.

SEC source: 0001193125-25-283953 · ownership.xml · nonDerivative · entry 1

Hunt Jonathan Robert · CIK 0001375410 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,800

F1 · price: The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.0235 to $2.0300, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price in the transactions described in this footnote.

SEC source: 0001193125-25-281626 · ownership.xml · nonDerivative · entry 1

Williamson Robert F III · CIK 0001397331 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · RFW3 Revocable Trust

Disclosed balance after: 9,864

SEC source: 0000950170-25-113245 · ownership.xml · derivative · entry 1

Sendek Joel · CIK 0001720875 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 600,000

Underlying: Common Stock · 600,000 shares

Expires 2035-09-04

F1 · derivative.exercise_date: The options vest over a four-year period, with one-fourth (1/4) vesting and becoming exercisable on September 4, 2026, and the remaining options vesting and becoming exercisable ratably over the following 36 months, subject to the continuous service of the Reporting Person as of each vesting date.

SEC source: 0000950170-25-113243 · ownership.xml · derivative · entry 1

Martinez Maria E · CIK 0001761768 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2035-09-03

F1 · derivative.exercise_date: Options vest and become exercisable over three years in 36 substantially equal monthly installments beginning on the date that is one month after the Grant Date, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0000950170-25-048698 · ownership.xml · nonDerivative · entry 2

Williamson Robert F III · CIK 0001397331 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,982

F1 · price: The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.12 to $2.1697, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price in the transaction described in this footnote.

SEC source: 0000950170-25-048691 · ownership.xml · nonDerivative · entry 1

Woods Lori A · CIK 0001393007 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Woods Family Living Trust

Disclosed balance after: 183,460

SEC source: 0000950170-25-048775 · ownership.xml · nonDerivative · entry 2

Spoor Johan M. · CIK 0001535289 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Child #1

Disclosed balance after: 4,650

F3 · price: The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.1900 to $2.2450, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price in the transaction described in this footnote.

SEC source: 0000950170-25-048775 · ownership.xml · nonDerivative · entry 1

Spoor Johan M. · CIK 0001535289 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,383

F1 · price: The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.1900 to $2.3000, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each separate price in the transaction described in this footnote.

F2 · balance_after: Previous Form 4s filed on behalf of the Reporting Person under-reported the Reporting Person's holdings by 1,100 shares of Common Stock. The amount reported in this Form 4 reflects the correct amount.

SEC source: 0000950170-25-048698 · ownership.xml · nonDerivative · entry 1

Williamson Robert F III · CIK 0001397331 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,837

SEC source: 0000950170-25-048696 · ownership.xml · nonDerivative · entry 1

Graham Juan · CIK 0001879223 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,354

F1 · price: The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.19 to $2.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price in the transaction described in this footnote.

SEC source: 0000950170-25-033675 · ownership.xml · derivative · entry 1

Puhlmann Markus · CIK 0001965071 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 165,000

Underlying: Common Stock · 165,000 shares

Expires 2035-03-03

F1 · date: The option grant was approved by the Compensation Committee of the Issuer's Board of Directors on February 13, 2025, with a grant date of March 3, 2025 (the "Grant Date"), and represents the Reporting Person's annual equity award for 2025.

F2 · derivative.exercise_date: Option vests and becomes exercisable over four years in 48 substantially equal monthly installments beginning on the date that is one month after the Grant Date, subject to the Reporting Person's continued service on each vesting date.

SEC source: 0000950170-25-033665 · ownership.xml · derivative · entry 1

Hunt Jonathan Robert · CIK 0001375410 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2035-03-03

F1 · date: The option grant was approved by the Compensation Committee of the Issuer's Board of Directors on February 13, 2025, with a grant date of March 3, 2025 (the "Grant Date"), and represents the Reporting Person's annual equity award for 2025.

F2 · derivative.exercise_date: Option vests and becomes exercisable over four years in 48 substantially equal monthly installments beginning on the date that is one month after the Grant Date, subject to the Reporting Person's continued service on each vesting date.

SEC source: 0000950170-25-033662 · ownership.xml · derivative · entry 1

Spoor Johan M. · CIK 0001535289 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 650,000

Underlying: Common Stock · 650,000 shares

Expires 2035-03-03

F1 · date: The option grant was approved by the Issuer's Board of Directors on February 12, 2025, with a grant date of March 3, 2025 (the "Grant Date"), and represents the Reporting Person's annual equity award for 2025.

F2 · derivative.exercise_date: Option vests and becomes exercisable over four years in 48 substantially equal monthly installments beginning on the date that is one month after the Grant Date, subject to the Reporting Person's continued service on each vesting date.

SEC source: 0000950170-25-033649 · ownership.xml · derivative · entry 1

HENSON HEIDI · CIK 0001283301 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2035-03-03

F1 · date: The option grant was approved by the Issuer's Board of Directors on February 12, 2025, with a grant date of March 3, 2025, and represents the Reporting Person's annual equity award for 2025.

F2 · derivative.exercise_date: Option vests in full on March 3, 2026, subject to the Reporting Person's continued service on the vesting date.

SEC source: 0000950170-25-033637 · ownership.xml · derivative · entry 1

Williamson Robert F III · CIK 0001397331 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2035-03-03

F1 · date: The option grant was approved by the Issuer's Board of Directors on February 12, 2025, with a grant date of March 3, 2025, and represents the Reporting Person's annual equity award for 2025.

F2 · derivative.exercise_date: Option vests in full on March 3, 2026, subject to the Reporting Person's continued service on the vesting date.

SEC source: 0000950170-25-033626 · ownership.xml · derivative · entry 1

Morich Frank · CIK 0001748615 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2035-03-03

F1 · date: The option grant was approved by the Issuer's Board of Directors on February 12, 2025, with a grant date of March 3, 2025, and represents the Reporting Person's annual equity award for 2025.

F2 · derivative.exercise_date: Option vests in full on March 3, 2026, subject to the Reporting Person's continued service on the vesting date.

SEC source: 0000950170-25-033614 · ownership.xml · derivative · entry 1

Woods Lori A · CIK 0001393007 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2035-03-03

F1 · date: The option grant was approved by the Issuer's Board of Directors on February 12, 2025, with a grant date of March 3, 2025, and represents the Reporting Person's annual equity award for 2025.

F2 · derivative.exercise_date: Option vests in full on March 3, 2026, subject to the Reporting Person's continued service on the vesting date.

SEC source: 0000950170-25-002927 · ownership.xml · derivative · entry 1

Graham Juan · CIK 0001879223 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 400,000

Underlying: Common Stock · 400,000 shares

Expires 2035-01-06

F1 · derivative.exercise_date: The options vest over a four-year period, with one-fourth (1/4) vesting and becoming exercisable on January 6, 2026, and the remaining options vesting and becoming exercisable ratably over the following 36 months, subject to the continuous service of the Reporting Person as of each vesting date.

SEC source: 0000950170-24-133355 · ownership.xml · nonDerivative · entry 1

Spoor Johan M. · CIK 0001535289 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,257

F1 · price: The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.7596 to $3.7700, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price in the transactions described in this footnote.

SEC source: 0000950170-24-134067 · ownership.xml · nonDerivative · entry 1

HENSON HEIDI · CIK 0001283301 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Revocable Trust

Disclosed balance after: 25,975

SEC source: 0000950170-24-130754 · ownership.xml · nonDerivative · entry 3

Spoor Johan M. · CIK 0001535289 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · By IRA of Spouse

Disclosed balance after: 66,600

SEC source: 0000950170-24-130754 · ownership.xml · nonDerivative · entry 2

Spoor Johan M. · CIK 0001535289 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · By IRA of Reporting Owner

Disclosed balance after: 5,400

SEC source: 0000950170-24-130754 · ownership.xml · nonDerivative · entry 1

Spoor Johan M. · CIK 0001535289 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 152,072

F1 · price: The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.645 to $3.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price in the transactions described in this footnote.

SEC source: 0000950170-24-131251 · ownership.xml · nonDerivative · entry 2

Williamson Robert F III · CIK 0001397331 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 430,058

SEC source: 0000950170-24-131251 · ownership.xml · nonDerivative · entry 1

Williamson Robert F III · CIK 0001397331 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 427,439

SEC source: 0000950170-24-131250 · ownership.xml · nonDerivative · entry 4

Hunt Jonathan Robert · CIK 0001375410 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,800

SEC source: 0000950170-24-131250 · ownership.xml · nonDerivative · entry 3

Hunt Jonathan Robert · CIK 0001375410 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,800

SEC source: 0000950170-24-131250 · ownership.xml · nonDerivative · entry 2

Hunt Jonathan Robert · CIK 0001375410 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,400

SEC source: 0000950170-24-131250 · ownership.xml · nonDerivative · entry 1

Hunt Jonathan Robert · CIK 0001375410 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,371

SEC source: 0000950170-24-084754 · ownership.xml · derivative · entry 1

Austin Mark John · CIK 0001713059 · VP Finance/Prin Fin&Acct Offic

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,500

Underlying: Common Stock · 34,500 shares

Expires 2034-07-17

F1 · derivative.exercise_date: Option vests over four years with 1/48th of the shares subject to such option vesting and becoming exercisable in substantially equal monthly installments on the monthly anniversary after the Grant Date (07/17/2024), subject to a continued service relationship.

SEC source: 0000950170-24-076736 · ownership.xml · derivative · entry 1

Williamson Robert F III · CIK 0001397331 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,000

Underlying: Common Stock · 23,000 shares

Expires 2034-06-20

F1 · derivative.exercise_date: This option shall fully vest on the first anniversary after the Grant Date (06/20/2024), subject to a continued service relationship.

SEC source: 0000950170-24-076727 · ownership.xml · derivative · entry 1

Morich Frank · CIK 0001748615 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,000

Underlying: Common Stock · 23,000 shares

Expires 2034-06-20

F1 · derivative.exercise_date: This option shall fully vest on the first anniversary after the Grant Date (06/20/2024), subject to a continued service relationship.

SEC source: 0000950170-24-076724 · ownership.xml · derivative · entry 1

Woods Lori A · CIK 0001393007 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,000

Underlying: Common Stock · 23,000 shares

Expires 2034-06-20

F1 · derivative.exercise_date: This option shall fully vest on the first anniversary after the Grant Date (06/20/2024), subject to a continued service relationship.

SEC source: 0000950170-24-076719 · ownership.xml · derivative · entry 1

HENSON HEIDI · CIK 0001283301 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,000

Underlying: Common Stock · 23,000 shares

Expires 2034-06-20

F1 · derivative.exercise_date: This option shall fully vest on the first anniversary after the Grant Date (06/20/2024), subject to a continued service relationship.

SEC source: 0000950170-24-076716 · ownership.xml · derivative · entry 1

Spoor Johan M. · CIK 0001535289 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Common Stock · 500,000 shares

Expires 2034-06-20

F1 · derivative.exercise_date: Option vests over four years with 1/48th of the shares subject to such option vesting and becoming exercisable in substantially equal monthly installments on the monthly anniversary after the Grant Date (06/20/2024), subject to a continued service relationship.